July 2018

Imbed Biosciences’ Clinical Successes to be Highlighted at SAWC Fall 2018

Madison, WI, July 27, 2018 – Imbed Biosciences, a developer of advanced biomaterials and soft tissue repair devices, announced today that clinical results documenting the use of its flagship product, MicroLyte® Ag Matrix resorbable antimicrobial wound matrix, will be presented at the Fall Symposium on Advanced Wound Care (SAWC) in Las Vegas, NV from November 2-4, 2018.  The company will also have a presence in the exhibitor space at booth #104.  SAWC is the nation’s largest interdisciplinary wound care forum.

The poster presentations, delivered by several of Imbed’s clinical collaborators, will highlight results in a variety of complex, chronic wounds and surgical applications.  The clinical case series were conducted independently at Rush University Medical Center (Chicago, IL), East Tennessee State University (Johnson City, TN), Duke Wound Management Clinic (Durham, NC), and the Institute for Advanced Wound Care (Montgomery, AL), and typically evaluated wound closure after application of MicroLyte® Ag Matrix to diabetic wounds, leg ulcers, an infected surgical site, and a radiation wound.  In one series, MicroLyte® Ag Matrix was also implanted in non-healing diabetic ulcers.

“The work that will be presented at SAWC represents a pivotal point for Imbed.  We are excited to see positive clinical outcomes in the hands of skilled wound healing practitioners.  We believe that these improved clinical outcomes will naturally lead to improved economic outcomes for small independent practices and large healthcare systems, alike” said Ankit Agarwal, President and CEO of Imbed Biosciences. “We are grateful to be working with collaborators who continually push the bounds of what we know MicroLyte® Ag Matrix can do.”

Additionally, prospective users who visit the SAWC exhibit hall will get an up-close look at Imbed’s groundbreaking, FDA-cleared MicroLyte® Ag Matrix resorbable antimicrobial wound matrix.   MicroLyte® Ag Matrix is primarily composed of an ultrathin, resorbable polymeric film, which means it never needs to be removed from the wound bed.  MicroLyte® Ag Matrix is also fully synthetic, so there is no risk of disease transmission from animal based-components and it has a long shelf-life (2 years or more) under ambient conditions.  MicroLyte® Ag Matrix is cleared for application in acute wounds such as lacerations, skin tears, abrasions, surgical wounds (e.g., donor and graft sites, incisions), partial thickness first- and second-degree burns, and partial to full-thickness dermal ulcers such as, diabetic, decubitus, venous stasis, arterial stasis ulcers.  The product may be applied daily or up to every 3 days, depending on the wound and the healing progression. The duration of the treatment depends on wound type and healing conditions.

Poster presentations of interest include:

The Use of an Absorbable Polyvinyl/Polymeric Microfilm Matrix with Silver in the Treatment of Venous Ulcers: A Pilot Study

Terry Treadwell, MD, Donna Walker, LPN, Maggie Taylor, NA, Angela Pickens, RN, Jessica Baker, RN

Institute for Advanced Wound Care, Montgomery, AL

 

The Efficacy of an Ultrathin Bioresorbable Silver Impregnated Polymeric Multilayer Matrix in the Treatment of Chronic Wounds and as an Implantable Material for at Risk Surgical Wounds

Ryan Chatelain, DPM

East Tennessee State University, Johnson City, TN

 

Problematic Leg Ulcers Require Innovative Solutions

Amelia B. Beatty, NP, Penny Jones, NP

Duke Wound Management Clinic, Durham, NC

 

An Ultrathin Bioresorbable Matrix with Antimicrobial Silver in the Treatment of Chronic Contaminated Wounds

Thea P. Price, MD

Rush University Medical Center, Chicago, IL

 

About Imbed Biosciences, Inc.

Imbed Biosciences is a privately held medical device company developing next-generation medical devices for the management of burns, chronic ulcers, gastro-intestinal defects, and soft-tissue repair. The company has a portfolio of products in development based on its patented MicroLyte® matrix polymeric multilayer platform that presents bioactive molecules on tissue surfaces to combat local pain and infections, support soft-tissue repair, and reduce antibiotic/opioid abuse. Imbed is backed by venture capital group WISC Partners based in Madison, WI, and has received research grants from the National Institutes of Health and the National Science Foundation. For more information, please visit www.imbedbio.com, www.MicroLyteAg.com, facebook.com/imbedbio, or @MicroLyteAgMtrx on twitter.

 

Imbed Biosciences Receives ISO 13485:2016 Certification

Madison, WI, July 3, 2018 – Imbed Biosciences, a developer of advanced biomaterials and soft tissue repair devices, announced today that the company has formally received its ISO 13485:2016 certificate.  The new certificate supersedes the existing certification and confirms that the company is compliant with the newest international standard governing the quality manufacture of medical devices.  The transition audit was conducted by British Standards Institution (BSI), a UK standards body and global business certification company.

“This transition to the new version of ISO 13485 is a great accomplishment for our team.  It allows Imbed’s partners and customers to have the highest level of confidence in the quality of our products.  Furthermore, updated ISO certification will help enable us to market our products internationally.  This is a key element of our application for CE marking for MicroLyte® Ag Matrix, which will be submitted later this quarter” said Jeff Dalsin, Vice President of Product Development and Quality.

About Imbed Biosciences, Inc.

Imbed Biosciences is a privately held medical device company developing next-generation medical devices for the management of burns, chronic ulcers, gastro-intestinal defects, and soft-tissue repair. The company has a portfolio of products in development based on its patented MicroLyte® matrix polymeric multilayer platform that presents bioactive molecules on tissue surfaces to combat local pain and infections, support soft-tissue repair, and reduce antibiotic/opioid abuse. Imbed is backed by venture capital group WISC Partners based in Madison, WI, and has received research grants from the National Institutes of Health and the National Science Foundation. For more information, please visit www.imbedbio.com, www.MicroLyteAg.com, facebook.com/imbedbio, or @MicroLyteAgMtrx on twitter.